Enzo Biochem ROA 2010-2023 | ENZ
Current and historical return on assets (ROA) values for Enzo Biochem (ENZ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Enzo Biochem ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2023-01-31 |
$-0.04B |
$0.08B |
-38.78% |
| 2022-10-31 |
$-0.03B |
$0.09B |
-27.41% |
| 2022-07-31 |
$-0.02B |
$0.10B |
-17.27% |
| 2022-04-30 |
$-0.01B |
$0.10B |
-6.44% |
| 2022-01-31 |
$0.00B |
$0.11B |
0.00% |
| 2021-10-31 |
$0.01B |
$0.11B |
4.46% |
| 2021-07-31 |
$0.01B |
$0.11B |
6.17% |
| 2021-04-30 |
$0.00B |
$0.11B |
0.88% |
| 2021-01-31 |
$-0.01B |
$0.11B |
-9.67% |
| 2020-10-31 |
$-0.02B |
$0.11B |
-18.26% |
| 2020-07-31 |
$-0.03B |
$0.11B |
-24.63% |
| 2020-04-30 |
$-0.03B |
$0.12B |
-26.67% |
| 2020-01-31 |
$0.00B |
$0.12B |
0.87% |
| 2019-10-31 |
$0.00B |
$0.13B |
0.93% |
| 2019-07-31 |
$0.00B |
$0.11B |
2.99% |
| 2019-04-30 |
$0.00B |
$0.11B |
2.02% |
| 2019-01-31 |
$-0.02B |
$0.09B |
-23.59% |
| 2018-10-31 |
$-0.02B |
$0.09B |
-15.65% |
| 2018-07-31 |
$-0.01B |
$0.10B |
-10.38% |
| 2018-04-30 |
$-0.01B |
$0.11B |
-4.65% |
| 2018-01-31 |
$-0.00B |
$0.11B |
-1.85% |
| 2017-10-31 |
$-0.00B |
$0.11B |
-1.86% |
| 2017-07-31 |
$-0.00B |
$0.11B |
-1.86% |
| 2017-04-30 |
$0.03B |
$0.11B |
31.26% |
| 2017-01-31 |
$0.03B |
$0.11B |
31.68% |
| 2016-10-31 |
$0.04B |
$0.11B |
42.22% |
| 2016-07-31 |
$0.05B |
$0.11B |
52.48% |
| 2016-04-30 |
$0.02B |
$0.08B |
22.74% |
| 2016-01-31 |
$0.02B |
$0.08B |
22.70% |
| 2015-10-31 |
$0.01B |
$0.07B |
7.66% |
| 2015-07-31 |
$-0.00B |
$0.07B |
-4.80% |
| 2015-04-30 |
$-0.01B |
$0.06B |
-22.76% |
| 2015-01-31 |
$-0.01B |
$0.06B |
-17.60% |
| 2014-10-31 |
$-0.01B |
$0.06B |
-17.89% |
| 2014-07-31 |
$-0.01B |
$0.06B |
-16.60% |
| 2014-04-30 |
$-0.01B |
$0.06B |
-16.95% |
| 2014-01-31 |
$-0.02B |
$0.06B |
-27.71% |
| 2013-10-31 |
$-0.02B |
$0.06B |
-30.38% |
| 2013-07-31 |
$-0.02B |
$0.06B |
-30.89% |
| 2013-04-30 |
$-0.04B |
$0.06B |
-67.19% |
| 2013-01-31 |
$-0.04B |
$0.06B |
-54.42% |
| 2012-10-31 |
$-0.04B |
$0.07B |
-45.92% |
| 2012-07-31 |
$-0.04B |
$0.07B |
-41.30% |
| 2012-04-30 |
$-0.02B |
$0.10B |
-14.71% |
| 2012-01-31 |
$-0.01B |
$0.10B |
-13.27% |
| 2011-10-31 |
$-0.02B |
$0.10B |
-14.75% |
| 2011-07-31 |
$-0.01B |
$0.11B |
-11.69% |
| 2011-04-30 |
$-0.02B |
$0.11B |
-13.30% |
| 2011-01-31 |
$-0.02B |
$0.11B |
-15.75% |
| 2010-10-31 |
$-0.02B |
$0.12B |
-18.60% |
| 2010-07-31 |
$-0.02B |
$0.12B |
-18.78% |
| 2010-04-30 |
$-0.02B |
$0.12B |
-17.32% |
| 2010-01-31 |
$-0.02B |
$0.13B |
-15.85% |
| 2009-10-31 |
$-0.02B |
$0.13B |
-14.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.102B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
